DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mozobil (Plerixafor Subcutaneous) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Mozobil® (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).

DOSAGE AND ADMINISTRATION

Recommended Dosage and Administration

Vials should be inspected visually for particulate matter and discoloration prior to administration and should not be used if there is particulate matter or if the solution is discolored.

Begin treatment with Mozobil after the patient has received G-CSF once daily for four days.  [see Dosage and Administration Administer Mozobil approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days.

The recommended dose of Mozobil is 0.24 mg/kg body weight by subcutaneous (SC) injection. Use the patient’s actual body weight to calculate the volume of Mozobil to be administered. Each vial delivers 1.2 mL of 20 mg/mL solution, and the volume to be administered to patients should be calculated from the following equation:

    0.012 X patient’s actual body weight (in kg) = volume to be administered (in mL)

In clinical studies, Mozobil dose has been calculated based on actual body weight in patients up to 175% of ideal body weight. Mozobil dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated.

Based on increasing exposure with increasing body weight, the plerixafor dose should not exceed 40 mg/day.  [see Clinical Pharmacology ]  

Recommended Concomitant Medications

Administer daily morning doses of G-CSF 10 micrograms/kg for 4 days prior to the first evening dose of Mozobil and on each day prior to apheresis. [see Clinical Studies ]

Dosing in Renal Impairment

In patients with moderate and severe renal impairment (estimated creatinine clearance (CLCR) ≤ 50 mL/min), reduce the dose of Mozobil by one-third to 0.16 mg/kg as shown in Table 1. If CLCR is ≤ 50 mL/min the dose should not exceed 27 mg/day, as the mg/kg-based dosage results in increased plerixafor exposure with increasing body weight.  [see Clinical Pharmacology ]   Similar systemic exposure is predicted if the dose is reduced by one-third in patients with moderate and severe renal impairment compared with subjects with normal renal function.  [see Clinical Pharmacology ]  

Table 1: Recommended Dosage of Plerixafor in Patients with Renal Impairment
     Estimated Creatinine Clearance    
(mL/min)
Dose
> 50     0.24 mg/kg once daily (not to exceed 40 mg/day)     
≤ 50     0.16 mg/kg once daily (not to exceed 27 mg/day)     

The following (Cockroft-Gault) formula may be used to estimate CLCR

    Males:
    Creatinine clearance (mL/min) = weight (kg) X (140 – age in years)
                                                            72 X serum creatinine (mg/dL)

    Females:
    Creatinine clearance (mL/min) = 0.85 X value calculated for males

There is insufficient information to make dosage recommendations in patients on hemodialysis.

DOSAGE FORMS AND STRENGTHS

Single-use vial containing 1.2 mL of a 20 mg/mL solution.

HOW SUPPLIED/STORAGE AND HANDLING

Each single-use vial is filled to deliver 1.2 mL of 20 mg/mL solution containing 24 mg of plerixafor.

NDC Number: 58468-0140-1


  • Store at 25oC (77oF); excursions permitted to 15o-30oC (59o-86oF). [see USP Controlled Room temperature]
  • Each vial of Mozobil is intended for single use only. Any unused drug remaining after injection must be discarded.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017